Unresectable Malignant Solid Neoplasm Recruiting Phase 2 Trials for Nilotinib (DB04868)

Indication	Status	Phase
DBCOND0110416 (Unresectable Malignant Solid Neoplasm)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Screening	Alpelisib (DB12015) Binimetinib (DB11967) Fluorouracil (DB00544) Fulvestrant (DB00947) Hydrogen (DB15127) Ipatasertib (DB11743) Leucovorin (DB00650) Neratinib (DB11828) Nilotinib (DB04868) Olaparib (DB09074) Oxaliplatin (DB00526) Paclitaxel (DB01229) Palbociclib (DB09073) Panitumumab (DB01269) Selumetinib (DB11689) Sotorasib (DB15569) Sulfate ion (DB14546)